151 related articles for article (PubMed ID: 37777743)
21. Left Ventricular Systolic Function After 3 Months of SGLT2 Inhibitor Therapy in Heart Failure Patients with Reduced Ejection Fraction.
Mustapic I; Bakovic D; Susilovic-Grabovac Z; Borovac JA
J Cardiovasc Transl Res; 2023 Oct; 16(5):987-998. PubMed ID: 37155137
[TBL] [Abstract][Full Text] [Related]
22. SGLT2 Inhibitors: New Hope for the Treatment of Acute Myocardial Infarction?
Wu YJ; Wang SB; Wang LS
Am J Cardiovasc Drugs; 2022 Nov; 22(6):601-613. PubMed ID: 35947249
[TBL] [Abstract][Full Text] [Related]
23. SGLT-2 inhibitors and in-stent restenosis-related events after acute myocardial infarction: an observational study in patients with type 2 diabetes.
Marfella R; Sardu C; D'Onofrio N; Fumagalli C; Scisciola L; Sasso FC; Siniscalchi M; Marfella LV; D'Andrea D; Minicucci F; Signoriello G; Cesaro A; Trotta MC; Frigé C; Prattichizzo F; Balestrieri ML; Ceriello A; Calabrò P; Mauro C; Del Viscovo L; Paolisso G
BMC Med; 2023 Feb; 21(1):71. PubMed ID: 36829203
[TBL] [Abstract][Full Text] [Related]
24. Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World).
Udell JA; Yuan Z; Rush T; Sicignano NM; Galitz M; Rosenthal N
Circulation; 2018 Apr; 137(14):1450-1459. PubMed ID: 29133607
[TBL] [Abstract][Full Text] [Related]
25. Cardiovascular and mortality benefits of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia.
Real J; Vlacho B; Ortega E; Vallés JA; Mata-Cases M; Castelblanco E; Wittbrodt ET; Fenici P; Kosiborod M; Mauricio D; Franch-Nadal J
Cardiovasc Diabetol; 2021 Jul; 20(1):139. PubMed ID: 34243779
[TBL] [Abstract][Full Text] [Related]
26. Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study.
Rau M; Thiele K; Hartmann NK; Schuh A; Altiok E; Möllmann J; Keszei AP; Böhm M; Marx N; Lehrke M
Cardiovasc Diabetol; 2021 Jan; 20(1):6. PubMed ID: 33413355
[TBL] [Abstract][Full Text] [Related]
27. Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction.
Yurista SR; Silljé HHW; Oberdorf-Maass SU; Schouten EM; Pavez Giani MG; Hillebrands JL; van Goor H; van Veldhuisen DJ; de Boer RA; Westenbrink BD
Eur J Heart Fail; 2019 Jul; 21(7):862-873. PubMed ID: 31033127
[TBL] [Abstract][Full Text] [Related]
28. Study on the application effect of bisoprolol combined with sacubitril valsartan sodium tablets in the cardiac rehabilitation of patients with acute myocardial infarction combined with left heart failure after percutaneous coronary intervention (PCI).
Chen C; Wu X; Li Y; Peng Y
Ann Palliat Med; 2021 May; 10(5):5455-5461. PubMed ID: 34044572
[TBL] [Abstract][Full Text] [Related]
29. Elevated circulating level of β-aminoisobutyric acid (BAIBA) in heart failure patients with type 2 diabetes receiving sodium-glucose cotransporter 2 inhibitors.
Katano S; Yano T; Kouzu H; Nagaoka R; Numazawa R; Yamano K; Fujisawa Y; Ohori K; Nagano N; Fujito T; Nishikawa R; Ohwada W; Katayose M; Sato T; Kuno A; Furuhashi M
Cardiovasc Diabetol; 2022 Dec; 21(1):285. PubMed ID: 36539818
[TBL] [Abstract][Full Text] [Related]
30. Comparison the effects of finerenone and SGLT2i on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus: A network meta-analysis.
Li X; Wu H; Peng H; Jiang H
Front Endocrinol (Lausanne); 2022; 13():1078686. PubMed ID: 36589800
[TBL] [Abstract][Full Text] [Related]
31. Effects of empagliflozin in women and men with acute myocardial infarction: An analysis from the EMMY trial.
Sourij C; Aziz F; Tripolt NJ; Siller-Matula J; Pferschy PN; Kolesnik E; Wallner M; Eyileten C; Postula M; Oulhaj A; Sourij H; von Lewinski D;
Hellenic J Cardiol; 2024; 75():3-8. PubMed ID: 37236318
[TBL] [Abstract][Full Text] [Related]
32. Adoption of New Glucose-Lowering Medications in the U.S.-The Case of SGLT2 Inhibitors: Nationwide Cohort Study.
McCoy RG; Dykhoff HJ; Sangaralingham L; Ross JS; Karaca-Mandic P; Montori VM; Shah ND
Diabetes Technol Ther; 2019 Dec; 21(12):702-712. PubMed ID: 31418588
[No Abstract] [Full Text] [Related]
33. Can sodium-glucose cotransporter 2 inhibitors be beneficial in patients with acute myocardial infarction?
von Lewinski D; Benedikt M; Tripolt N; Wallner M; Sourij H; Kolesnik E
Kardiol Pol; 2021; 79(5):503-509. PubMed ID: 34125922
[TBL] [Abstract][Full Text] [Related]
34. Incident heart failure and myocardial infarction in sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitor users.
Zhou J; Lee S; Leung KSK; Wai AKC; Liu T; Liu Y; Chang D; Wong WT; Wong ICK; Cheung BMY; Zhang Q; Tse G
ESC Heart Fail; 2022 Apr; 9(2):1388-1399. PubMed ID: 35132823
[TBL] [Abstract][Full Text] [Related]
35. Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis.
Kaze AD; Zhuo M; Kim SC; Patorno E; Paik JM
Cardiovasc Diabetol; 2022 Mar; 21(1):47. PubMed ID: 35321742
[TBL] [Abstract][Full Text] [Related]
36. Blood pressure-lowering effects of SGLT2 inhibitors and GLP-1 receptor agonists for preventing of cardiovascular events and death in type 2 diabetes: a systematic review and meta-analysis.
Diallo A; Carlos-Bolumbu M; Galtier F
Acta Diabetol; 2023 Dec; 60(12):1651-1662. PubMed ID: 37439858
[TBL] [Abstract][Full Text] [Related]
37. Sodium Glucose Cotransporter-2 Inhibition for Acute Myocardial Infarction: JACC Review Topic of the Week.
Udell JA; Jones WS; Petrie MC; Harrington J; Anker SD; Bhatt DL; Hernandez AF; Butler J
J Am Coll Cardiol; 2022 May; 79(20):2058-2068. PubMed ID: 35589167
[TBL] [Abstract][Full Text] [Related]
38. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.
Furtado RHM; Bonaca MP; Raz I; Zelniker TA; Mosenzon O; Cahn A; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Ruff CT; Nicolau JC; Gause-Nilsson IAM; Fredriksson M; Langkilde AM; Sabatine MS; Wiviott SD
Circulation; 2019 May; 139(22):2516-2527. PubMed ID: 30882239
[TBL] [Abstract][Full Text] [Related]
39. Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry.
Paolisso P; Bergamaschi L; Santulli G; Gallinoro E; Cesaro A; Gragnano F; Sardu C; Mileva N; Foà A; Armillotta M; Sansonetti A; Amicone S; Impellizzeri A; Casella G; Mauro C; Vassilev D; Marfella R; Calabrò P; Barbato E; Pizzi C
Cardiovasc Diabetol; 2022 May; 21(1):77. PubMed ID: 35570280
[TBL] [Abstract][Full Text] [Related]
40. Impact of dapagliflozin on cardiac function following anterior myocardial infarction in non-diabetic patients - DACAMI (a randomized controlled clinical trial).
Dayem KA; Younis O; Zarif B; Attia S; AbdelSalam A
Int J Cardiol; 2023 May; 379():9-14. PubMed ID: 36889650
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
